Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pegfilgrastim.

Fenella Willis1, Ruth Pettengell

  • 1St. George's Hospital, Cranmer Terrace, London SW17 0RE, U.K. fwillis@sghms.ac.uk

Expert Opinion on Biological Therapy
|January 9, 2003
PubMed
Summary

Pegfilgrastim, a long-acting form of G-CSF, effectively prevents chemotherapy-induced neutropenia with a single dose. This offers significant benefits for patients undergoing cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Successful serial plasmapheresis for solar urticaria, a case report and literature review.

The Journal of dermatological treatment·2024
Same author

Laboratory practice is central to earlier myeloma diagnosis: Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology services.

British journal of haematology·2024
Same author

Investigation and management of the monoclonal gammopathy of undetermined significance: A British Society for Haematology Good Practice Paper.

British journal of haematology·2023
Same author

FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions.

BMC medical genomics·2023
Same author

Chemotherapy May Obviate Prophylactic Femoral Nail Surgery for Multiple Myeloma Patients With High Mirels' Score Lesions and Impending Pathological Hip Fracture.

Cureus·2023
Same author

An Economic Model to Establish the Costs Associated With Routes to Presentation for Patients With Multiple Myeloma in the United Kingdom.

Value in health regional issues·2023

Area of Science:

  • Oncology
  • Hematology

Background:

  • Granulocyte colony-stimulating factor (G-CSF) is crucial for managing chemotherapy-induced neutropenia.
  • G-CSF's short half-life requires frequent daily injections, impacting patient convenience.
  • G-CSF is also utilized for mobilizing peripheral blood progenitor cells for transplantation.

Purpose of the Study:

  • To evaluate the efficacy and safety of pegfilgrastim, a novel sustained-action G-CSF.
  • To compare single-dose pegfilgrastim with daily filgrastim in preventing chemotherapy-induced neutropenia.
  • To assess the clinical and quality of life benefits of pegfilgrastim's once-per-cycle administration.

Main Methods:

  • Clinical trials comparing single-dose pegfilgrastim to daily filgrastim.
  • Assessment of neutropenia incidence, duration, febrile neutropenia, hospitalizations, and antibiotic use.
  • Evaluation of patient-reported outcomes and quality of life.

Main Results:

  • Single-dose pegfilgrastim demonstrated comparable safety and efficacy to daily filgrastim in reducing chemotherapy-induced neutropenia.
  • Pegfilgrastim administration resulted in significant clinical benefits and improved quality of life due to its convenient dosing schedule.
  • Ongoing trials are investigating pegfilgrastim's potential in mobilizing peripheral blood progenitor cells.

Conclusions:

  • Pegfilgrastim is a safe and effective alternative to daily G-CSF for prophylaxis of chemotherapy-induced neutropenia.
  • The sustained action of pegfilgrastim offers substantial patient convenience and clinical advantages.
  • Pegfilgrastim is approved in the US for neutropenia prophylaxis and treatment, with further research into stem cell mobilization.

Related Experiment Videos